The first market opportunity is represented by breast cancer patients being treated in the adjuvant setting. These patients are generally newly diagnosed with breast cancer, have had surgery and are now embarked on a first course of treatment to supplement the surgical procedure. There are approximately 200,000 new cases of breast cancer each year. Nearly all of these patients are candidates for adjuvant treatment and will therefore be candidates for our planned HERmark adjuvant breast cancer assay. The second market opportunity is represented by patients with metastatic breast cancer. These are patients for whom the cancer has spread beyond the breast, and in many cases multiple treatments may have already been provided. There are an additional 60,000 women annually who are newly diagnosed with Stage IV breast cancer or who have progressed from earlier stages of disease. "We are proceeding on parallel paths to generate clinical data to validate the ability of HERmark to predict patient response in each of these clinical settings," continued Young.
"We have recently begun our work in the adjuvant use of Herceptin with the initiation of a pivotal study in up to 1,600 patient samples from a well controlled and highly credible clinical study," said Young. "This study is designed to evaluate HERmark as a tool for predicting response to Herceptin in the adjuvant setting and is a very important platform for validating the VeraTag technology and the first HERmark products. We have already received and processed the first samples and expect to receive the remaining samples for processing over the next several months."
Monogram is continuing its evaluation of HERmark in metastatic breast
cancer patients, where in three separate cohorts of patients involving a
total of approximately 250 patients, consistent relationships have been
identified between assay measurem
|SOURCE Monogram Biosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved